{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004607","form_type":"8-K","ticker":"ANIK","cik":"0000898437","company_name":"Anika Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.239001+00:00","generated_at":"2026-05-31T11:30:59.495950+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anika Q2 revenue $41.9M (-5% YoY); net loss $0.1M; launches Integrity Implant System","bullets":["Revenue $41.9M, down 5% YoY; OA Pain Mgmt $26.7M (-9%), Joint Preservation $13.5M (+7%).","Net loss $0.1M ($0.01/sh); adjusted net income $2.5M ($0.17/sh); adjusted EBITDA $6.3M.","Full market release of Integrity Implant System (HA scaffold) in July; >300 cases by >60 surgeons.","Guidance: FY2024 revenue $168-$173M (1-4% growth); adjusted EBITDA towards lower end of $25-$30M.","New $40M share repurchase program; $15M under 10b5-1 plan initiated May 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004607","json":"https://secwatch.observer/filing/0001171843-24-004607.json","markdown":"https://secwatch.observer/filing/0001171843-24-004607.md","text":"https://secwatch.observer/filing/0001171843-24-004607.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/898437/000117184324004607/0001171843-24-004607-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/898437/000117184324004607/f8k_080824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:30:59.495950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}